CLSD Clearside Biomedical Inc.

0.8
+0.05  (+6%)
Previous Close 0.75
Open 0.76
Price To Book 2.35
Market Cap 30,204,049
Shares 37,759,781
Volume 363,054
Short Ratio
Av. Daily Volume 1,115,776
Stock charts supplied by TradingView

NewsSee all news

  1. Clearside Biomedical Announces Multiple Presentations to be Given at the American Academy of Ophthalmology (AAO) 2019 Annual Meeting

    ALPHARETTA, Ga., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people

  2. Clearside Biomedical Featured at Multiple European Scientific Retinal Congresses

    ALPHARETTA, Ga., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people

  3. REGENXBIO Announces Exclusive Worldwide Option and License Agreement with Clearside Biomedical for Evaluation of In-Office Delivery Platform for RGX-314

    ROCKVILLE, Md. and ALPHARETTA, Ga., Sept. 4, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based

  4. Clearside Biomedical to Present at the Janney Montgomery Scott Healthcare Conference

    ALPHARETTA, Ga., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people

  5. Clearside Biomedical Provides New Drug Application Update for XIPEREᵀᴹ (triamcinolone acetonide suprachoroidal injectable suspension)

    ALPHARETTA, Ga., Aug. 22, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data released May 31, 2018 - mixed data. 12.3 ETDRS letters compared to 13.5 ETDRS letters in control arm.
Suprachoroidal CLS-TA - TYBEE
Diabetic Macular Edema (DME)
Phase 3 data released November 5, 2018 did not meet primary endpoint.
Suprachoroidal CLS-TA - SAPPHIRE
Macular edema associated with retinal vein occlusion (RVO)
PDUFA date October 19, 2019. Noted August 22, 2019 that a CRL is expected and will resubmit in 1Q 2020 with requested stability data.
Suprachoroidal CLS-TA - PEACHTREE
Macular edema associated with non-infectious uveitis

Latest News

  1. Clearside Biomedical Announces Multiple Presentations to be Given at the American Academy of Ophthalmology (AAO) 2019 Annual Meeting

    ALPHARETTA, Ga., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people

  2. Clearside Biomedical Featured at Multiple European Scientific Retinal Congresses

    ALPHARETTA, Ga., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people

  3. REGENXBIO Announces Exclusive Worldwide Option and License Agreement with Clearside Biomedical for Evaluation of In-Office Delivery Platform for RGX-314

    ROCKVILLE, Md. and ALPHARETTA, Ga., Sept. 4, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based

  4. Clearside Biomedical to Present at the Janney Montgomery Scott Healthcare Conference

    ALPHARETTA, Ga., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people

  5. Clearside Biomedical Provides New Drug Application Update for XIPEREᵀᴹ (triamcinolone acetonide suprachoroidal injectable suspension)

    ALPHARETTA, Ga., Aug. 22, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people